Showing 1 - 20 results of 30,660 for search '(( 100 ns decrease ) OR ((( _ largest decrease ) OR ( _ ((a decrease) OR (small decrease)) ))))', query time: 0.65s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

    Published 2025
    “…<p><b>(A)</b> A significant decrease in the proliferative clonal capacity of U87MG colonies was observed with 70ΜM and 100ΜM SHG-44 treatment. …”
  5. 5
  6. 6
  7. 7
  8. 8

    Why does task performance decrease with burst length? by Swathi Anil (17382903)

    Published 2025
    “…See <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1013125#pcbi.1013125.s001" target="_blank">S1 Appendix</a>.…”
  9. 9

    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

    Published 2025
    “…<p><b>(A)</b> A significant reduction in colony-forming ability was observed in U87MG cells treated with 100ΜM SHG-44 compared to 100ΜM cis-platin and the untreated control. …”
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

    Published 2025
    “…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
  16. 16
  17. 17

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  18. 18
  19. 19
  20. 20